Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (AML) (VALOR)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Sunesis Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01191801
First received: August 27, 2010
Last updated: October 10, 2013
Last verified: October 2013